Last reviewed · How we verify
GBP510 adjuvanted with AS03
GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity.
GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity. Used for Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline).
At a glance
| Generic name | GBP510 adjuvanted with AS03 |
|---|---|
| Sponsor | SK Bioscience Co., Ltd. |
| Drug class | Recombinant protein vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
GBP510 contains recombinant protein antigens that are presented to the immune system to generate both cellular and humoral immune responses. AS03 is an oil-in-water adjuvant that amplifies and accelerates the immune response to the vaccine antigen, improving efficacy and potentially broadening the immune response profile. This combination approach is typical for next-generation vaccine development to enhance protection against infectious diseases or cancer.
Approved indications
- Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline)
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
- Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) (PHASE3)
- Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (PHASE2)
- Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GBP510 adjuvanted with AS03 CI brief — competitive landscape report
- GBP510 adjuvanted with AS03 updates RSS · CI watch RSS
- SK Bioscience Co., Ltd. portfolio CI